- Home
- IDYA vs PBI Comparison
IDYA vs PBI Comparison
Compare IDYA & PBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- PBI
- Stock Information
- Founded
- IDYA 2015
- PBI 1920
- Country
- IDYA United States
- PBI United States
- Employees
- IDYA N/A
- PBI N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- PBI Office Equipment/Supplies/Services
- Sector
- IDYA Health Care
- PBI Miscellaneous
- Exchange
- IDYA Nasdaq
- PBI Nasdaq
- Market Cap
- IDYA 2.3B
- PBI 2.0B
- IPO Year
- IDYA 2019
- PBI N/A
- Fundamental
- Price
- IDYA $27.16
- PBI $12.28
- Analyst Decision
- IDYA Buy
- PBI
- Analyst Count
- IDYA 14
- PBI 0
- Target Price
- IDYA $49.17
- PBI N/A
- AVG Volume (30 Days)
- IDYA 953.6K
- PBI 2.9M
- Earning Date
- IDYA 11-03-2025
- PBI 07-30-2025
- Dividend Yield
- IDYA N/A
- PBI 2.61%
- EPS Growth
- IDYA N/A
- PBI N/A
- EPS
- IDYA N/A
- PBI N/A
- Revenue
- IDYA $7,000,000.00
- PBI $1,970,913,000.00
- Revenue This Year
- IDYA $62.30
- PBI N/A
- Revenue Next Year
- IDYA $285.58
- PBI N/A
- P/E Ratio
- IDYA N/A
- PBI N/A
- Revenue Growth
- IDYA N/A
- PBI N/A
- 52 Week Low
- IDYA $13.45
- PBI $6.22
- 52 Week High
- IDYA $39.30
- PBI $13.11
- Technical
- Relative Strength Index (RSI)
- IDYA 70.30
- PBI 60.38
- Support Level
- IDYA $24.04
- PBI $11.82
- Resistance Level
- IDYA $25.39
- PBI $12.44
- Average True Range (ATR)
- IDYA 1.05
- PBI 0.35
- MACD
- IDYA 0.16
- PBI 0.05
- Stochastic Oscillator
- IDYA 99.45
- PBI 85.87
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About PBI Pitney Bowes Inc.
Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the globe. The company's reportable segments are SendTech Solutions and Presort Services. SendTech Solutions includes the revenue and related expenses from physical and digital mailing and shipping technology solutions, financing, services, supplies and other applications to help simplify and save on the sending, tracking and receiving of letters, parcels and flats. Presort Services includes the revenue and related expenses from sortation services to qualify large volumes of First Class Mail, Marketing Mail and Marketing Mail Flats/Bound Printed Matter for postal worksharing discounts. It derives maximum revenue from SendTech Solutions.